The NO-CUT trial at ESMO 2024: can more aggressive treatment prevent the need for surgery?
Colorectal Cancer Canada Blog
by Iris Karry
1M ago
September 2024 Findings from the NO-CUT trial were presented at the European Society for Medical Oncology (ESMO) Congress 2024 this September in Barcelona, Spain. The study explored the efficacy of more aggressive initial treatment known as total neoadjuvant therapy followed by non-operative management in patients with mismatch repair proficient (pMMR) locally advanced rectal cancer. Total ..read more
Visit website
Omitting 5-FU Bolus May Reduce Side Effects in Patients with Advanced Gastrointestinal Cancers
Colorectal Cancer Canada Blog
by Iris Karry
1M ago
September 2024 Findings from research published in the Journal of the National Comprehensive Cancer Network found that when the 5-fluorouracil (5-FU) bolus from combination chemotherapy treatments such as FOLFOX (Folinic acid, 5-Fluorouracil, Oxaliplatin), FOLFIRI (Folinic acid, 5-Fluorouracil, Irinotecan), or FOLFIRINOX (Folinic acid, 5-Fluorouracil, Irinotecan, Oxaliplatin), was removed, it helped to improve the tolerability of the ..read more
Visit website
Melissa Groff
Colorectal Cancer Canada Blog
by Iris Karry
2M ago
In this video, Melissa shares her experience with colorectal cancer. As a young wife and mother of 3, Melissa faced unique challenges as she navigated her diagnosis, treatment, and recovery ..read more
Visit website
Rapid liquid biopsy testing now available at William Osler Health System – Brampton, Ontario
Colorectal Cancer Canada Blog
by Iris Karry
2M ago
July 2024 Liquid biopsy testing is an important tool in precision oncology that can be used to diagnose cancer and tailor cancer treatments to a patient’s tumour. William Osler Health System in Brampton, Ontario is now the first Canadian hospital to do in-house liquid biopsy testing for cancer care. Precision oncology: the science of using ..read more
Visit website
Anne Perry
Colorectal Cancer Canada Blog
by Iris Karry
3M ago
Meet Anne Perry, founder of "Test for Toby." As a caregiver to her husband during his battle with colorectal cancer, Anne turned her experiences into a mission for early detection and support and became an inspirational force behind the Shelburne, Ontario edition of Push For Your Tush. In this video, she shares her journey, emphasizing ..read more
Visit website
There are No Bad Emotions!
Colorectal Cancer Canada Blog
by Iris Karry
3M ago
When we experience large emotions, our first instinct is to want to get rid of them, avoid them, or push them so far down we forget about them. What if I told you that this can make the emotions larger, stronger, and more likely to impact you? Finding ways to make friends with the emotions ..read more
Visit website
Update from the TRANSMET trial: survival benefit seen for patients with unresectable colorectal liver metastases
Colorectal Cancer Canada Blog
by Iris Karry
3M ago
August 2024 Patients living with colorectal liver metastases that cannot be removed by surgery experience poor long-term survival outcomes. The TRANSMET trial aimed to assess the efficacy of chemotherapy plus liver transplant compared to chemotherapy alone for this subgroup of colorectal cancer patients. Updated findings from the TRANSMET trial presented at the European Society for ..read more
Visit website
What is the impact of red and processed meat consumption on occurrence of chronic diseases and mortality?
Colorectal Cancer Canada Blog
by Iris Karry
3M ago
August 2024 A recent study conducted in the United States showed that when unprocessed red meat and processed meat consumption was reduced by 30% over a period of 10 years, it led to significant decreases in chronic diseases and death. Unprocessed red meats: meats such as beef, pork, and lamb that have not been cured ..read more
Visit website
Long-lasting response in a subset of locally advanced rectal cancer patients in response to dostarlimab immunotherapy
Colorectal Cancer Canada Blog
by Iris Karry
4M ago
June 2024 Early clinical results have shown that locally advanced (stage III) mismatch repair deficient (dMMR) rectal cancers can respond very well to immunotherapy alone, therefore allowing patients to avoid treatment with chemotherapy, radiation, or surgery. The long-term impact of immunotherapy treatment on this patient population, however, is unknown. A phase II study investigated the efficacy of the immunotherapy agent dostarlimab in patients with locally advanced dMMR or microsatellite instability high (MSI-H) rectal cancer. 47 patients with dMMR locally advanced rectal cancer were enrol ..read more
Visit website
Immunotherapy prior to surgery may improve outcomes for some patients with colorectal cancer
Colorectal Cancer Canada Blog
by Iris Karry
4M ago
June 2024 A phase II study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting aimed to investigate whether the immunotherapy agent pembrolizumab given before surgery may improve outcomes in certain patients with stage II or III dMMR/MSI-H colorectal cancer (CRC).   Immunotherapy: a class of drugs that stimulate the body’s own immune system to more effectively target cancer cells. dMMR/MSI-H : this stands for MisMatch Repair deficient, Microsatellite Instability High. This is an important biomarker in colorectal cancer which suggests that the tumour is more l ..read more
Visit website

Follow Colorectal Cancer Canada Blog on FeedSpot

Continue with Google
Continue with Apple
OR